Skip to main content

Advertisement

SpringerLink
Log in

Drug combinations with quercetin: doxorubicin plus quercetin in human breast cancer cells

  • Original Article
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Abstract

Purpose

Doxorubicin is a first-line chemotherapeutic for breast cancer; however, it is associated with severe side effects to non-tumoral tissues. Thus, it is necessary to develop new therapeutic combinations to improve doxorubicin effects at lower concentration of the drug associated with protective effects for non-tumoral cells. In this work, we evaluated whether the plant-derived flavonoid quercetin may represent such an agent.

Methods

The effects of doxorubicin and quercetin as single agents and in combination were evaluated on cell survival, DNA and protein synthesis, oxidative stress, migratory potential and cytoskeleton and nucleus structure in highly invasive and poorly invasive human breast cancer cells in comparison with non-tumoral human breast cells.

Results

In human breast cancer cells, quercetin potentiated antitumor effects of doxorubicin specifically in the highly invasive breast cancer cells and attenuated unwanted cytotoxicity to non-tumoral cells. Quercetin interfered with cell metabolism, GST activity, cytoskeleton and invasive properties specifically in breast tumor cells compared with non-tumoral breast cells. Doxorubicin induced DNA damage in tumor and non-tumor cells; however, quercetin reduced this damage only in non-tumoral cells, thus offering a protective effect for these cells. Quercetin also induced polynucleation in aggressive tumor cells, which was maintained in combination with doxorubicin.

Conclusions

By combining quercetin with doxorubicin, an increase in doxorubicin effects was obtained specifically in the highly invasive breast cancer cells, while in non-tumoral cells quercetin reduced doxorubicin cytotoxic side effects. Thus, quercetin associated with doxorubicin demonstrated very promising properties for developing chemotherapeutics combinations for the therapy of breast cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

Similar content being viewed by others

References

  1. Hortobagyi GN (1998) Treatment of breast cancer. N Engl J Med 339:974–984

    Article  PubMed  CAS  Google Scholar 

  2. Andreetta C, Minisini AM, Miscoria M, Puglisi F (2010) First-line chemotherapy with or without biologic agents for metastatic breast cancer. Crit Rev Oncol Hematol 76:99–111

    Article  PubMed  Google Scholar 

  3. Minotti G, Menna P, Salvatorelli E, Cairo G, Gianni L (2004) Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev 56:185–229

    Article  PubMed  CAS  Google Scholar 

  4. Gajewski E, Gaur S, Akman SA, Matsumoto L, van Balgooy JN, Doroshow JH (2007) Oxidative DNA base damage in MCF-10A breast epithelial cells at clinically achievable concentrations of doxorubicin. Biochem Pharmacol 73:1947–1956

    Article  PubMed  CAS  Google Scholar 

  5. Adlercreutz H, Mousavi Y, Hockerstedt K (1992) Diet and breast cancer. Acta Oncol 31:175–181

    Article  PubMed  CAS  Google Scholar 

  6. Ferry DR, Smith A, Malkhandi J, Fyfe DW, deTakats PG, Anderson D, Baker J, Kerr DJ (1996) Phase I clinical trial of the flavonoid quercetin: pharmacokinetics and evidence for in vivo tyrosine kinase inhibition. Clin Cancer Res 2:659–668

    PubMed  CAS  Google Scholar 

  7. Moon YJ, Wang L, DiCenzo R, Morris ME (2008) Quercetin pharmacokinetics in humans. Biopharm Drug Dispos 29:205–217

    Article  PubMed  CAS  Google Scholar 

  8. Rodgers EH, Grant MH (1998) The effect of the flavonoids, quercetin, myricetin and epicatechin on the growth and enzyme activities of MCF7 human breast cancer cells. Chem Biol Interact 116:213–228

    Article  PubMed  CAS  Google Scholar 

  9. Paliwal S, Sundaram J, Mitragotri S (2005) Induction of cancer-specific cytotoxicity towards human prostate and skin cells using quercetin and ultrasound. Br J Cancer 92:499–502

    PubMed  CAS  Google Scholar 

  10. Wang L, Tu YC, Lian TW, Hung JT, Yen JH, Wu MJ (2006) Distinctive antioxidant and antiinflammatory effects of flavonols. J Agric Food Chem 54:9798–9804

    Article  PubMed  CAS  Google Scholar 

  11. Bach A, Bender-Sigel J, Schrenk D, Flugel D, Kietzmann K (2010) The antioxidant quercetin inhibits cellular proliferation via HIF-1-dependent induction of p21WAF. Antioxid Redox Signal 13:437–448

    Article  PubMed  CAS  Google Scholar 

  12. Kawahara T, Kawaguchi-Ihara N, Okuhashi Y, Itoh M, Nara N, Tohda S (2009) Cyclopamine and quercetin suppress the growth of leukemia and lymphoma cells. Anticancer Res 29:4629–4632

    PubMed  CAS  Google Scholar 

  13. Caltagirone S, Rossi C, Poggi A, Ranelletti FO, Natali PG, Brunetti M, Aiello FM, Piantelli M (2000) Flavonoids apigenin and quercetin inhibit melanoma growth and metastatic potential. Int J Cancer 87:595–600

    Article  PubMed  CAS  Google Scholar 

  14. Hsieh TC, Wu JM (2009) Targeting CWR22Rv1 prostate cancer cell proliferation and gene expression by combinations of the phytochemicals EGCG, genistein and quercetin. Anticancer Res 29:4025–4032

    PubMed  CAS  Google Scholar 

  15. Ferraresi R, Troiano L, Roat E, Lugli E, Nemes E, Nasi M, Pinti M, Fernandez MI, Cooper EL, Cossarizza A (2005) Essential requirement of reduced glutathione (GSH) for the anti-oxidant effect of the flavonoid quercetin. Free Radic Res 39:1249–1258

    Article  PubMed  CAS  Google Scholar 

  16. Lo HW, Ali-Osman F (2007) Genetic polymorphism and function of glutathione S-transferases in tumor drug resistance. Curr.Opin. Pharmacol. 7:367–374

    Article  PubMed  CAS  Google Scholar 

  17. Tsuchida S, Sato K (1992) Glutathione transferases and cancer. Crit Rev Biochem Mol Biol 27:337–384

    Article  PubMed  CAS  Google Scholar 

  18. Hayes JD, Flanagan JU, Jowsey IR (2005) Glutathione transferases. Ann Rev Pharmacol Toxicol 45:51–88

    Article  CAS  Google Scholar 

  19. Perquin M, Oster T, Maul A, Froment N, Untereiner M, Bagrel D (2000) The glutathione-related detoxification pathway in the human breast: a highly coordinated system disrupted in the tumour tissues. Cancer Lett 158:7–16

    Article  PubMed  CAS  Google Scholar 

  20. Akbas SH, Timur M, Ozben T (2005) The effect of quercetin on topotecan cytotoxicity in MCF-7 and MDA-MB 231 human breast cancer cells. J Surg Res 125(125):49–55

    Article  PubMed  CAS  Google Scholar 

  21. Schlachterman A, Valle F, Wall KM, Azios NG, Castillo L, Morell L, Washington AV, Cubano LA, Dharmawardhane SF (2008) Combined resveratrol, quercetin, and catechin treatment reduces breast tumor growth in a nude mouse model. Transl Oncol 1:19–27

    PubMed  Google Scholar 

  22. Du G, Lin H, Wang M, Zhang S, Wu X, Lu L, Ji L, Yu L (2010) Quercetin greatly improved therapeutic index of doxorubicin against 4T1 breast cancer by its opposing effects on HIF-1alpha in tumor and normal cells. Cancer Chemother Pharmacol 65:277–287

    Article  PubMed  CAS  Google Scholar 

  23. Du G, Lin H, Yang Y, Zhang S, Wu X, Wang M, Ji L, Lu L, Yu L, Han G (2010) Dietary quercetin combining intratumoral doxorubicin injection synergistically induces rejection of established breast cancer in mice. Int Immunopharmacol 10:819–826

    Article  PubMed  CAS  Google Scholar 

  24. Vaclavikova R, Kondrova E, Ehrlichova M, Boumendjel A, Kovar J, Stopka P, Soucek P, Gut I (2008) The effect of flavonoid derivatives on doxorubicin transport and metabolism. Bioorg Med Chem 16:2034–2042

    Article  PubMed  CAS  Google Scholar 

  25. Juillerat-Jeanneret L, Chapuis Bernasconi C, Bricod C, Gros S, Trepey S, Benhattar J, Janzer RC (2008) Heterogeneity of human glioblastoma: glutathione-S-transferase and methylguanine methyl transferase. Cancer Invest 26:597–608

    Article  PubMed  CAS  Google Scholar 

  26. Collins AR (2004) The comet assay for DNA damage and repair: principles, applications, and limitations. Mol Biotechnol 26:249–261

    Article  PubMed  CAS  Google Scholar 

  27. Nagaraja GM, Othman M, Fox BP, Alsaber R, Pellegraino CM, Zeng Y, Khanna R, Tamburini P, Swaroop A, Kandpal RP (2006) Gene expression signatures and biomarkers of noninvasive and invasive breast cancer cells: comprehensive profiles by representational difference analysis, microarrays and proteomics. Oncogene 25:2328–2338

    Article  PubMed  CAS  Google Scholar 

  28. Wang K, Ramji S, Bhathena A, Lee C, Riddick DS (1999) Glutathione S-transferase in wild-type and doxorubicin-resistant MCF-7 human breast cancer cell lines. Xenobiotica 29:155–170

    Article  PubMed  CAS  Google Scholar 

  29. Gewirtz DA (1999) A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. Biochem Pharmacol 57:727–741

    Article  PubMed  CAS  Google Scholar 

  30. Topcu Z (2001) DNA topoisomerases as targets for anticancer drugs. J Clin Pharm Ther 26:405–416

    Article  PubMed  CAS  Google Scholar 

  31. Momparler RM, Karon M, Siegel SE, Avila F (1976) Effect of adriamycin on DNA, RNA, and protein synthesis in cell-free systems and intact cells. Cancer Res 36:2891–2895

    PubMed  CAS  Google Scholar 

  32. Diaz Bessone MI, Berardi DE, Campodonico PB, Todaro LB, Lothstein L, Bal de Kier Joffe ED, Urtreger AJ (2010) Involvement of PKC delta (PKCdelta) in the resistance against different doxorubicin analogs. Breast Cancer Res Treat (in press)

  33. Conklin CMJ, Bechberger JF, MacFabe D, Guthrie N, Kurowska EM, Naus CC (2007) Genistein and quercetin increase connexin43 and suppress growth of breast cancer cells. Carcinogenesis 28:93–100

    Article  PubMed  CAS  Google Scholar 

  34. van Zanden JJ, Ben Hamman O, van Iersel ML, Boeren S, Cnubben NH, Lo Bello M, Vervoort J, van Bladeren PJ, Rietjens IM (2003) Inhibition of human glutathione S-transferase P1–1 by the flavonoid quercetin. Chem Biol Interact 145:139–148

    Article  PubMed  Google Scholar 

  35. Gutzeit HO, Henker Y, Kind B, Franz A (2004) Specific interactions of quercetin and other flavonoids with target proteins are revealed by elicited fluorescence. Biochem Biophys Res Commun 318:490–495

    Article  PubMed  CAS  Google Scholar 

  36. Murakami A, Ashida H, Terao J (2008) Multitargeted cancer prevention by quercetin. Cancer Lett 269:315–325

    Article  PubMed  CAS  Google Scholar 

  37. Cai Q, Rahn RO, Zhang R (1997) Dietary flavonoids, quercetin, luteolin and genistein, reduce oxidative DNA damage and lipid peroxidation and quench free radicals. Cancer Lett 119:99–107

    Article  PubMed  CAS  Google Scholar 

  38. Biscardi JS, Ishizawar RC, Silva CM, Parsons SJ (2000) Tyrosine kinase signalling in breast cancer: epidermal growth factor receptor and c-Src interactions in breast cancer. Breast Cancer Res 2:203–210

    Article  PubMed  CAS  Google Scholar 

  39. Lee KW, Kang NJ, Heo YS, Rogozin EA, Pugliese A, Hwang MK, Bowden GT, Bode AM, Lee HJ, Dong Z (2008) Raf and MEK protein kinases are direct molecular targets for the chemopreventive effect of quercetin, a major flavonol in red wine. Cancer Res 68:946–955

    Article  PubMed  CAS  Google Scholar 

  40. Roberts PJ, Der CJ (2007) Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene 26:3291–3310

    Article  PubMed  CAS  Google Scholar 

  41. Singhal RL, Yeh YA, Praja N, Olah E, Sledge GW, Weber G (1995) Quercetin down-regulates signal transduction in human breast carcinoma cells. Biochem Biophys Res Commun 208:425–431

    Article  PubMed  CAS  Google Scholar 

  42. Lin CW, Hou WC, Shen SC, Juan SH, Ko CH, Wang LM, Chen YC (2008) Quercetin inhibition of tumor invasion via suppressing PKC delta/ERK/AP-1-dependent matrix metalloproteinase-9 activation in breast carcinoma cells. Carcinogenesis 29:1807–1815

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

We want to thank Dr. C. Brisken for the kind gift of MCF-10A cells, Dr. F. Schmitt for very helpful discussions and comments, Ms. C. Chapuis Bernasconi for excellent technical assistance, and the European Community FP7 project “NanoTest” (grant No 2007-201335) for financial support (to BHK and LJJ). The results shown here are part of Master thesis work of E. Idrizi and D. Staedler at the University of Lausanne (UNIL).

Conflict of interest

The authors declare no conflict of interest.

Author information

Authors and Affiliations

  1. Centre Hospitalier Universitaire Vaudois (CHUV) and University of Lausanne (UNIL), Lausanne, Switzerland

    Davide Staedler, Elita Idrizi, Blanka Halamoda Kenzaoui & Lucienne Juillerat-Jeanneret

  2. Institute of Pathology, University of Lausanne, Rue du Bugnon 25, 1011, Lausanne, Switzerland

    Lucienne Juillerat-Jeanneret

Authors
  1. Davide Staedler
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Elita Idrizi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Blanka Halamoda Kenzaoui
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Lucienne Juillerat-Jeanneret
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Lucienne Juillerat-Jeanneret.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Staedler, D., Idrizi, E., Kenzaoui, B.H. et al. Drug combinations with quercetin: doxorubicin plus quercetin in human breast cancer cells. Cancer Chemother Pharmacol 68, 1161–1172 (2011). https://doi.org/10.1007/s00280-011-1596-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00280-011-1596-x

Keywords

Search

Navigation